Radius Health, Inc.

NASDAQ:RDUS

16.4 (USD) • At close November 1, 2024
Bedrijfsnaam Radius Health, Inc.
Symbool RDUS
Munteenheid USD
Prijs 16.4
Beurswaarde 456,567,800
Dividendpercentage 3.85%
52-weken bereik 12.69 - 31.7
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Jesper Hoiland
Website https://radiuspharm.com

An error occurred while fetching data.

Over Radius Health, Inc.

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical

Vergelijkbare Aandelen

Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc.

EWTX

34 USD

Eiger BioPharmaceuticals, Inc. logo

Eiger BioPharmaceuticals, Inc.

EIGR

1.725 USD

LianBio logo

LianBio

LIAN

0.319 USD

Zynex, Inc. logo

Zynex, Inc.

ZYXI

8.76 USD

Aadi Bioscience, Inc. logo

Aadi Bioscience, Inc.

AADI

1.99 USD

Talaris Therapeutics, Inc. logo

Talaris Therapeutics, Inc.

TALS

2.72 USD

Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc.

PHAT

18.27 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)